RecruitingNCT03848052

Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)

Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Lung Cancer in France Since 2015

Sponsor

UNICANCER

Enrollment

75,000 participants

Start Date

Oct 2, 2017

Study Type

OBSERVATIONAL

Conditions

Lung Cancer

Summary

This database compiles data from existing data available from patient's electronic medical records (EMR) at the 38 participating hospitals (20 French comprehensive cancer centers and 18 public hospitals).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting information about how the treatment of lung cancer has changed over time in France — including what medications were used, at what stage cancer was diagnosed, and how patients fared — by reviewing medical records of patients who received lung cancer treatment at participating French hospitals. **You may be eligible if...** - You are an adult (18 or older) - You were treated with radiation therapy or systemic cancer treatments (such as chemotherapy or immunotherapy) for lung cancer, OR you were diagnosed with metastatic (advanced, spread) lung cancer, at one of the participating hospitals during the study period **You may NOT be eligible if...** - There are no exclusion criteria — all eligible adult lung cancer patients at participating sites qualify Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(21)

Institut de Cancérologie de l'Ouest - Paul Papin

Angers, France

Institut Bergonié

Bordeaux, France

Centre François Baclesse

Caen, France

Centre Jean Perrin

Clermont-Ferrand, France

Hôpital Intercommunal de Créteil

Créteil, France

Centre Georges-François Leclerc

Dijon, France

Centre Oscar Lambret

Lille, France

Centre Léon Bérard

Lyon, France

Institut Paoli-Calmettes

Marseille, France

Institut régional du Cancer Montpellier / Val d'Aurelle

Montpellier, France

Groupe Hospitalier Région Mulhouse et Sud Alsace - Hôpital Emile Muller

Mulhouse, France

Institut de cancérologie de l'Ouest - René Gauducheau

Nantes, France

Centre Antoine Lacassagne

Nice, France

Institut Curie

Paris, France

Institut Jean Godinot

Reims, France

Centre Henri Becquerel

Rouen, France

Institut Curie - Hôpital René Huguenin

Saint-Cloud, France

Centre Paul Strauss

Strasbourg, France

Institut Claudius Regaud

Toulouse, France

Institut de Cancérologie de Lorraine

Vandœuvre-lès-Nancy, France

Institut Gustave Roussy

Villejuif, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03848052

Related Trials

Holistic Acupuncture for Patients With Chemotherapy Induced Nausea

NCT072011941 location

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

NCT0605169512 locations

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

NCT058005871 location

A Clinico-biological Database of Lung Cancers

NCT033878651 location

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566251 locations